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Standardised self-management kits for children with type 1 diabetes: 
pragmatic randomised trial of effectiveness and cost-effectiveness 
Abstract  
Objective: To estimate the effectiveness of standardised self-management kits for children with 
type 1 diabetes.  
Design: Pragmatic trial with randomisation ratio of 2 intervention: 1 control.  Qualitative process 
evaluation.  
Setting: 11 diabetes clinics in England and Wales.  
Participants: Between February 2010 and August 2011 we validly randomised 308 children aged 
six to 18 years; 201 received the intervention.  
Intervention: We designed kits to empower children to achieve glycaemic control, notably by 
recording blood glucose and titrating insulin.  The comparator was usual treatment.  
Outcome measures at 3 and 6 months: Primary: Diabetes PedsQL.  Secondary: HbA1c; General 
PedsQL; EQ-5D; healthcare resource use. 
Results:  Of the five  Diabetes PedsQL dimensions, Worry showed adjusted scores significantly 
favouring self-management kits at three months (mean child-reported difference = +5.87; 
standard error [SE] = 2.19; 95% confidence interval [CI] from +1.57 to +10.18; p = 0.008); but 
Treatment Adherence significantly favoured controls at six months (mean child-reported 
difference = -4.68; SE = 1.74; 95% CI from -8.10 to -1.25; p = 0.008).  Intervention children reported 
significantly worse changes between three and six months on four of the five Diabetes PedsQL 
dimensions and on the total score (mean difference = -3.20; SE = 1.33; 95% CI from -5.73 to -0.67; 
p = 0.020).  There was no evidence of change in HbA1c; only 18% of participants in each group 
achieved recommended levels at 6 months.  No serious adverse reactions attributable to the 
intervention or its absence were reported. 
Use of kits was poor.  Few children or parents associated blood glucose readings with better 
glycaemic control.  The kits, costing £185, alienated many children and parents.   
Conclusions: Standardised kits showed no evidence of benefit, inhibited diabetes self-
management and increased worry. Future research should study relationships between children 
and professionals, and seek new methods of helping children and parents to manage diabetes.   
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Trial registration: ISRCTN17551624 
Funding: National Institute for Health Research  
 
Kudos plain language summary  
Children and their parents find it very challenging to manage their type 1 diabetes well.   Daily self-
management is complex and involves adjusting the amount of insulin injected and sticking to 
specific foods and portion sizes to stay well.  The amount of sugar in the blood should also be 
measured regularly to make sure that levels are not too high or too low.  We worked with large 
numbers of children age 6-18years to design three age appropriate diabetes self-management 
kits. The kits contained everything that the children said that they needed to better manage their 
diabetes. We then tested the new self-management kits in a large trial to see if children who used 
the kits were better able to manage their diabetes compared to those who did not use the kits.  
The trial showed that the kits made no difference and in some cases their diabetes management 
became worse.  Over one third of children who were eligible did not want to take part in the trial.  
The kits caused some children to worry more and alienated both children and their parents.  We 
asked children and their parents why they did not find the kits helpful. They told us that they did 
not like anything that reminded them that they had diabetes. Nor did they fully understand what 
good diabetes management involved or the risks associated with not managing their diabetes well.  
Children frequently reported that they did not like attending children’s diabetes clinics or the 
authoritarian approach taken by diabetes professionals to their diabetes management.  We 
concluded that there needs to be a fresh approach to the way that children’s diabetes services are 
organised and managed.  New ideas are needed about how best to design children’s diabetes 
education.  
 
Strengths and limitations of this study  
 
• The self-management kits that were tested in this trial were designed with large numbers 
of children and young people and their parents in a 3 year study.  
• We conducted a fully powered pragmatic trial of children’s self-management kits in routine 
practice.  
• A third of eligible children and young people declined to participate in the trial.  
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• Our large process evaluation provided a detailed explanation of the mechanisms that 
appear to lead to negative outcomes and lack of engagement by children and parents.   
• The cost-effectiveness analysis was limited as there was no evidence of intervention effect.  
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Introduction 
Managing diabetes at all ages costs the National Health Service (NHS) nearly £10 billion a year; 
80% of this is for managing avoidable complications.1  Learning to manage one’s diabetes in 
childhood is important to prevent long-term and potentially life-threatening complications of poor 
glycaemic control.  Diabetes care pathways2-5 have been available for over a decade and the 
proportion of children in England and Wales who achieved the previous National Institute for 
Health and Care Excellence (NICE) target of an HbA1c level of ≤58 mmol/mol has slowly increased 
from 14.5% in 2009 to 15.8% in 2013 and 26.6% in 2015.6-8 In 2015 NICE further amended the 
target to ≤48mmol/mol.9  Schools vary considerably in the support given to children to manage 
their insulin administration, diet, and participation in extracurricular activities and sports.10 
Achieving optimal glycaemic control is most difficult during transition from paediatric to adult 
services when young people become independent of parents and families.11 
Optimal diabetes self-management requires titration of insulin doses against blood glucose levels, 
dietary intake and planned physical activities.3,9 This skill is essential  for children to participate 
fully in school life and social activities outside school.10   Models of children’s diabetes care 
emphasise a family-centred approach with intensive education and support following diagnosis, 
with increasing responsibility for care transferred to the child over time.6-7  There has been no 
standardisation of diabetes self-management information given to children to use at home and 
school.     
To prepare for the trial, research was undertaken in the current and a previous study with 
children, young people and parents to identify the types and formats of self-management 
information likely to inspire behaviour change in children and  young people with diabetes.12,13  
Our systematic review of educational and support interventions to improve diabetes self-
management in schools revealed no effective interventions, but many barriers to self-
management when children were away from their parents.10 Hence the goal of this trial was to 
evaluate whether standardised age-appropriate self-management kits motivate children and their 
families to avoid complications caused by uncontrolled blood sugar levels.  Our primary aim was to 
assess whether the kits enabled children to manage their type 1 diabetes by titrating their insulin 
dose against regular blood glucose readings.  Our secondary aim was to assess how children, their 
families and diabetes professionals perceived and used these kits.   
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The subsequent availability of published reports for five other contemporaneous trials of United 
Kingdom (UK) children’s diabetes education interventions created a new opportunity to review all 
six trials and explore why none of these six interventions had any effect.  In particular, since the 
original report was pubished in the NIHR journals library12, we have now reanalysed HbA1c, a 
secondary outcome measure in our trial so that results can be discussed in relation to five 
contemporaneous UK trials and other international studies.  We have also undertaken a more 
detailed analysis of the sub-domains of Diabetes PedsQL, the primary outcome measure of our 
trial,  to better understand the benefits and harms of the intervention.  
 
Methods 
Study design and participants 
We conducted a pragmatic randomised trial, including economic and process evaluations, in NHS 
paediatric diabetes clinics in England and Wales (ISRCTN 17551624).12-14  The Wales Multi-Centre 
Research Ethics Committee gave approval (08/MRE09/57). The Medicines for Children Research 
Network (England) and the Children and Young People Research Network (Wales) recruited 
diabetes multi-disciplinary teams in 11 NHS District General Hospitals.   
 
Intervention  
Children in the comparator group received treatment as usually provided in each of the 11 
diabetes clinics.14 A record of  ‘usual care’ was made in order to have a clear idea of the 
comparator with which EPIC was being compared.  Children in the intervention group received a 
standardised but flexible self-management kit known as “Evidence into Practice – Information 
Counts” (EPIC).  Following extensive literature review, consultation and fieldwork,10,12-14 EPIC 
comprised: 
 
• Three age-specific (6-10 years, 11-15 or 16-18) diabetes self-management kits comprising 
booklets, magazines, leaflets, CDs and website links;  
• Three corresponding diaries for those using insulin injections*; 
• One diary for children using insulin pumps*; 
• Sheets for recording carbohydrate intake; and 
• Stickers (6-15 years) and marker pens (11-15 years) for children to personalise their folder. 
*children could also use blood glucose recordings downloaded from their blood glucose 
monitors.  
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A detailed account of intervention development and the theoretical basis of the EPIC intervention 
is reported elsewhere.12  In brief, we designed EPIC so that children and young people had 
relevant information to self-manage their diabetes (with support from parents for younger 
children) consistent with relevant clinical guidelines,2-5 incorporating age-appropriate preferences 
for information13 and consistent with clinical practice in the UK NHS. Key features intended to 
appeal to children and engage them in EPIC included: presentation to and ownership by the child; 
age-appropriate messages stressing ‘top ten tips’ for self-management; the invitation ‘take me 
with you wherever you go’; contextual questions about self-management and life-style; 
integration into routine encounters with the child’s multi-disciplinary team, especially the 
Paediatrician and the Paediatric Diabetes Specialist Nurse (PDSN); scope for professionals and 
parents to tailor EPIC to each child and review at subsequent appointments; and encouraging the 
child to record blood glucose and insulin titration every day to share with professionals.  We 
invited diabetes team members to attend training in their hospital which described EPIC, 
introduced the manual, and suggested how to engage each child, and how to integrate EPIC into 
routine care.  
 
Random allocation 
Between February 2010 and August 2011 we screened diabetes outpatient clinic lists in 11 
hospitals for potentially eligible children between 6 and 18 years with type 1 diabetes.  We 
excluded children with communication difficulties, needle phobia, or other impairments judged 
inconsistent with the trial.  We sent invitation letters and age-specific information sheets to 
families of eligible children.  Research nurses independent of both clinical and research teams 
sought written informed consent to the trial from parents and children over 16 years, or assent 
from children under 16 years.  Consenting parents and their children provided baseline data.  
Research nurses then used a secure web-based dynamic randomisation system15 to allocate 
children at random between EPIC and treatment as usual, stratified by hospital, age, gender and 
whether two years had elapsed since diagnosis; the allocation ratio was two intervention 
participants for every control.  These nurses told children’s clinical teams of these allocations so 
they could initiate EPIC at the next consultation.  We followed these children for 6 months.   
 
Masking 
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Though it was neither desirable nor feasible to blind clinical staff or participants to treatment 
allocated, we sought to blind assessors.  Analysis was undertaken by an independent trial support 
unit.  
 
Outcome measures 
The primary outcome was children’s self-efficacy in coping with their diabetes, measured by child 
and (proxy) parent versions of the Diabetes PedsQL16 six months after randomisation, with interim 
scores at three months.  The Diabetes PedsQL comprises 33 items (32 for younger children) 
covering five domains – diabetes, treatment adherence, treatment barriers, communication and 
worry.  The resulting scores lie between zero and 100 with higher scores indicating better coping. 
Secondary outcomes comprised: HbA1c measured at routine quarterly clinics; health-related 
quality of life measured by child and (proxy) parent versions of the General PedsQL;17 and health-
related quality of life measured by the EQ-5D-3L.18  We used the youth version for children under 
16 years, the adult version for those over 16, and parents’ proxy scores for all children.  Follow-up 
questionnaires, completed after three and six months in clinic or by post, also sought data on 
episodes of diabetic ketoacidosis and health service use, especially hospital admissions for acute 
complications, recorded on a diabetes-specific version of the Client Service Receipt Inventory.19  
We checked health service use against children’s hospital notes.  
Children and parents also completed baseline questionnaires covering socio-demographic 
characteristics and the duration and self-management of their diabetes. Children received £10 
vouchers for each questionnaire they completed at 3 or 6 months.  Non-responders received both 
telephone and postal reminders after two and four weeks. 
We defined serious adverse events (SAEs) as adverse events that, in the judgement of the relevant 
site Principal Investigator, were lethal, life threatening, resulting in hospital admission, resulting in 
persistent or significant disability or incapacity, or otherwise medically significant.  We defined 
serious adverse reactions (SARs) as SAEs that, in the judgement of the Clinical Principal 
Investigator (CPI) and research team, were definitely, probably or possibly related to the EPIC 
intervention or to treatment as usual.  
 
Sample size  
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To yield 80% power of detecting an effect size of 0.4 in the primary outcome of self-efficacy when 
using a two-sided 5% significance level, we aimed to analyse 202 children, initially by recruiting 
252 children – 168 allocated to EPIC and 84 controls, thus allowing for losing 20% of participants to 
follow up.20,21  As fewer participants than expected initially responded to questionnaires, we 
reviewed these calculations in consultation with the Data Monitoring Committee and increased 
the target to 337 to allow for losing 40% to follow up.  We also introduced monetary vouchers for 
completed questionnaires.   
 
Statistical analyses 
Analysis was by treatment allocated.  We imputed missing quality of life data in accordance with 
published guidance for each measure. 22,23 We used the fully conditional specification technique 
and five multiple imputations across time points to impute these data.22  We compared 
differences between treatment groups using mixed models to undertake repeated-measures 
analysis of variance, adjusting for stratification variables and baseline values.  We estimated 
parameters for three fixed factors – the time-points of three and six months and treatment group.  
We modelled hospital as a random factor.  We included the interaction between treatment group 
and time-point to test whether differences between treatment groups varied between time-
points.  These analyses modelled diabetes self-efficacy (Diabetes PedsQL), quality of life (General 
PedsQL) and health utility (EQ-5D), both to study change in individuals, and in cohort analysis to 
compare change in group means.   
 
Economic analysis  
We costed the age-specific EPIC kits by recording quantities and costs of materials used to produce 
them, and estimating the mean additional time taken by PDSNs.  We collected retrospective data 
on children’s use of primary and secondary healthcare services over the previous three months.  
We applied national unit costs in 2010-11 pounds sterling (£) to these services.24,25  As we followed 
participants for only six months, we did not discount costs or effects.26  We undertook cost-
consequence analysis from an NHS perspective and tested the sensitivity of findings to the 
substitution of consultants for nurses in presenting the EPIC kits.  
 
Process evaluation  
After the trial we recruited a second sample for semi-structured recorded interviews in depth.  
The process evaluation was conducted up to December 2013.   We used purposive sampling to 
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generate maximum variation in the ages, genders, times since diagnosis, and types of insulin 
transfer (injection or pump) of 41 children allocated to EPIC, and 19 comparator children.  We also 
interviewed 66 parents and family members of these children.  These interviews explored: views 
and experiences of both EPIC kits and treatment as usual; how participants managed self-care at 
home and in school and other social contexts; and children’s interactions with diabetes teams.  
Before the trial we interviewed professionals in each of the 11 hospitals about their previous 
practice; after the trial we surveyed them by post about how they had implemented EPIC.  We 
recorded interviews, transcribed them verbatim, and analysed them using the thematic 
framework approach.27  We mapped the resulting themes onto the underlying theory and 
developed higher level themes and understanding in depth.   
As part of the process evaluation we also undertook a discourse analysis of a purposive sample of 
children’s diabetes resources used in the UK NHS.28  Discourse analysis is a way of identifying and 
analysing the assumptions made by information sources about their relationships with their 
readership, assumptions that had shaped the messages of the selected resources, some of which 
had appeared in the intervention pack and may also have been available to comparator children.    
Patient and public involvement 
Children, parents and public representatives were actively involved in an extensive three year 
prior study, as well as the current study to develop the educational intervention.12   A core set of 
diabetes education materials were co-designed by children with type 1 diabetes of various ages.  
Children and parents were represented in the trial advisory group.   All participants received a 
child-centred copy of the findings.  
 
Results 
 
Figures 1 and 2 show the flow of participants through the study.  We screened 1105 children 
identified as potentially eligible from the clinic lists of 11 participating hospitals: 146 (13.2%) were 
not eligible by the trial criteria, 335 (30.3%) declined to participate after receiving letters of 
invitation and trial information sheets, 287 (26.0%) were missed in clinic or did not join the trial for 
other reasons.  Hence we randomised 337 children.   
Insert Figures 1 and 2 
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Response rates  
Two protocol violations affected 29 children.  More importantly 21 intervention and 7 comparator 
children did not complete baseline questionnaires before receiving treatment within the trial, 
most because one centre allowed them to take questionnaires home for return by post.  The other 
violation randomised the same child twice following a change of web servers at another site. 
Fortunately sensitivity analysis including these 29 children showed essentially the same results.15 
Figure 2 shows that, of the 308 fully compliant children, 256 (84%) returned questionnaires at 3 
months, 266 (86%) did so at 6 months and imputation enabled us to analyse 293 (95%).  Thus the 
incentive of shopping vouchers achieved much higher response rates than our targets.  Hence the 
trial was better powered than planned.   
Baseline characteristics  
Table 1 shows characteristics of the 293 analysable participants at baseline. 
Table 1:  Characteristics of participants at baseline by allocated group  
  EPIC kit Treatment as 
usual 
N (row %) 190 (65%) 103 (35%) 
DEMOGRAPHIC CHARACTERISTICS 
[n (%) unless specified] 
    
Gender  Male 85 (45) 49 (48) 
  Female 105 (55) 54 (52) 
Age in years Range 6.3-18.9 6.4-18.4 
  Mean (SD) 12.4 (3.0) 12.7 (3.2) 
Ethnicity  White British 179 (94) 101 (98) 
  Other 11 (6)  2 (2)  
Education &  Secondary school 13 (42)  7 (33)  
employment Further Education College 13 (42) 12 (57) 
 Other 5 (16) 1 (5)  
  
Age <16 so not asked 159 86 
Living situation Owner occupied house/flat 156 (82) 86 (83) 
 Privately rented house/flat 20 (11) 6 (6) 
Housing assoc./local authority 14 (7) 11 (11) 
Years since diagnosis Range 0.8 – 16.7 1.2 – 15.7 
 Mean (SD) 7.4 (3.8) 8.0 (3.9) 
Type of insulin  Injections 167 (88) 87 (84) 
administration Pump 23 (12) 16 (16) 
Insulin regimen  Once a day 2 (1)  -  
 2 times a day 41 (25) 19 (22) 
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 3 times a day 14 (8)  10 (11)  
4 times a day 95 (57) 45 (52) 
  
Other (at least 5 times a day) 15 (9) 13 (15) 
Blood glucose tests None 1 (1) 1 (1)  
Once a day 4 (2) 1 (1) 
 2 times a day 7 (4)  5 (5)  
 3 times a day 31 (16) 16 (16) 
 4 times a day 89 (47) 50 (49) 
 Other (at least 5 times a day) 57 (30) 29 (28) 
  
Missing 1   1  
HbA1C   (%) 
 (mmol/mol) 1 
Range 5.9-14.0 
41.0-129.5 
6.0-13.7 
42.1-126.2 
Mean  8.77/72.3 8.59/70.4 
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QOL BASELINE MEASURES AT TRIAL ENTRY   
Child self-report 
PedsQL: Diabetes module 
(total scale score 100) 73.63 (14.68) 73.29 (12.17) 
 
PedsQL: Generic module 
(total scale score 100) 83.70 (12.36) 81.78 (12.63) 
 
EQ-5D utility score (total 
scale score 1) 0.9012 (0.1501) 0.8976 (0.1537) 
 
EQ-5D VAS (total scale 
score 100) 83.22 (16.98) 77.86 (18.89) 
Parent proxy 
PedsQL: Diabetes module 
(total scale score 100) 65.82 (15.35) 65.65 (14.02) 
 
PedsQL: Generic module 
 (total scale score 100) 77.86 (14.66) 77.78 (14.43) 
 
EQ-5D utility score (total 
scale score 1) 0.8499 (0.1733) 0.8231 (0.1800) 
  
EQ-5D VAS (total scale 
score100) 83.02 (16.40) 79.96 (19.11) 
 
1 Pooled estimates. 
 
Primary outcome 
Tables 2 and 3 show that, of the five dimensions of the Diabetes PedsQL, only Worry showed 
adjusted scores significantly favouring self-management kits at three months: the mean child-
reported difference was +5.87 with standard error [SE] of 2.19, generating statistical significance 
level (p) of 0.8% and a 95% confidence interval [CI] from +1.57 to +10.18.  At six months, however, 
only Treatment Adherence achieved significance – in favour of treatment as usual: the mean child-
reported difference was –4.68 with SE of 1.74, generating another p of 0.8% and 95% CI from –
8.10 to –1.25.  Even worse, intervention children reported significant adverse changes between 
three and six months on four of the five Diabetes PedsQL dimensions and thus on the total score: 
the mean child-reported difference was –3.20 with statistical significance level of 2.0% and 95% CI 
from –5.73 to –0.67. 
Secondary outcomes 
Moreover there was no evidence of change in HbA1c.  Participants started the trial with a mean 
baseline HbA1c of 72 mmol/mol. Whether adjusted by baseline scores and stratification variables 
or not, this mean remained virtually unchanged during the follow up period: after three months 
self-managing children had reduced their adjusted HbA1c by only –0.63 mmol/mol relative to 
comparator children (p=0.64; 95% CI from –3.31 to +2.04; after six months the reduction was only 
–0.19 mmol/mol (p=0.90; 95% CI from –3.07 to +2.70).  At baseline only 16% of children across 
both treatment groups had achieved HbA1c levels ≤ 58 mmol/mol, and at six months only 18%, 
thereby matching the national average in 2012/3.5    
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Tables 2 and 3 also show that the only statistically significant difference between groups in 
General PedsQL or EQ-5D-3L was that self-managing children reported that their School 
Functioning after six months was worse by –5.79 on average (p < 0.001; 95% CI from –9.21 to –
2.36). Those intervention children also reported significant adverse changes between three and six 
months on two of the four Diabetes PedsQL dimensions and thus on the total score: the mean 
child-reported difference was –5.78 (p=0.002; 95% CI from –9.39 to –2.17). 
However the parent-reported PedsQL scores, showed a different pattern from the child-reported 
scores: no delayed negative effects were apparent; instead comparator children were significantly 
better after three months in Diabetes Symptoms by –2.93 (p=0.036; 95% CI from –5.68 to –0.19); 
and in Treatment Adherence by –3.86 (p=0.026; 95% CI from –7.25 to –0.47). 
Adverse events  
Participating clinicians reported 31 serious adverse events to the trial team – 22 in the 
intervention group and 9 in the comparator group, yielding a relative risk of 1.33 (p=0.45; 95% CI 
from 0.63 to 2.77).  The CPI, and the Chairs of the Data Monitoring & Ethics Committee and the 
Trial Steering Committee, reviewed and confirmed these SAEs.  The CPI and research team judged 
that 4 SAEs from the Intervention Group and 2 from the Control Group were SARs possibly related to the 
EPIC intervention or to treatment as usual, yielding a relative risk of 1.08 (p=0.92; 95% CI from 0.20 to 
5.82).   
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Table 2: Mixed models adjusted by stratification variables and baseline values BY treatment allocated 
Outcome variable Difference (Epic Pack– Treatment as usual) Covariates/Cofactors sig at 5% 
 F(1,290) p Mean s.e. 95% CI  F(1,290) p 
Child self-report         
PedsQL: General          
Total score 0.76 0.384 -0.96 1.10 -3.13 to 1.21 Baseline 275 <0.001 
      Time-point 4.36 0.038 
      Treatment group by time-point 5.13 0.024 
Physical functioning 0.00 0.974 0.04 1.32 -2.56 to 2.65 Baseline 103 <0.001 
      Time-point 5.38 0.021 
      Treatment group by time-point 8.14 0.005 
Emotional functioning 0.08 0.780 -0.51 1.83 -4.12 to 3.09 Baseline 184 <0.001 
Social functioning 0.00 0.971 -0.05 1.46 -2.92 to 2.81 Baseline 181 <0.001 
School functioning 4.26 0.040 -2.90 1.40 -5.66 to -0.14 Baseline 271 <0.001 
      Treatment group by time-point 9.59 0.002 
PedsQL: Diabetes                 
Total score 0.07 0.798 -0.32 1.26 -2.80 to 2.16 Baseline 183 <0.001 
      Treatment group by time-point 5.44 0.020 
Diabetes symptoms 0.00 0.955 -0.09 1.55 -3.14 to 2.96 Baseline 170 <0.001 
Treatment barriers 0.02 0.876 -0.27 1.71 -3.64 to 3.10 Baseline 174 <0.001 
      Treatment group by time-point 4.19 0.042 
Treatment adherence 2.60 0.108 -2.38 1.47 -5.28 to 0.52 Baseline 78 <0.001 
      Treatment group-by-time-point 6.87 0.009 
Worry 2.76 0.098 3.23 1.94 -0.60 to 7.05 Baseline 176 <0.001 
      Treatment group by time-point 4.88 0.028 
Communication 0.13 0.720 0.69 1.93 -3.10 to 4.48 Baseline 107 <0.001 
      Treatment group-by-time-point 7.17 0.008 
EQ-5D  0.00 0.960 .001 .018 -.034 to .036 Baseline 115 <0.001 
      Gender 6.12 0.014 
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           Length of time since diagnosis 6.82 0.009 
EQ-5D: VAS  0.42 0.520 1.10 1.70 -2.26 to 4.45 Baseline 125 <0.001 
      Age 4.05 0.045 
Parent proxy         
PedsQL: General          
Total score 0.66 0.417 0.94 1.15 -1.33 to 3.20 Baseline 264 <0.001 
Physical functioning 2.61 0.107 2.22 1.38 -0.48 to 4.93 Baseline 94 <0.001 
Emotional functioning 0.06 0.799 -0.48 1.86 -4.15 to 3.20 Baseline 143 <0.001 
Social functioning 0.25 0.620 0.72 1.45 -2.13 to 3.57 Baseline 292 <0.001 
      Age 5.28 0.022 
School functioning 0.463 0.497 0.97 1.42 -1.84 to 3.77 Baseline 316 <0.001 
      Time point 6.81 0.010 
PedsQL: Diabetes                
Total score 2.36 0.125 -1.68 1.09 -3.82 to 0.47 Baseline 412 <0.001 
Diabetes symptoms 1.44 0.232 -1.55 1.29 -4.09 to 1.00 Baseline 390 <0.001 
Treatment barriers 0.57 0.452 -1.20 1.60 -4.36 to 1.95 Baseline 270 <0.001 
      Age 5.67 0.018 
Treatment adherence 6.15 0.014 -3.48 1.40 -6.23 to -0.72 Baseline 218 <0.001 
Worry 0.15 0.697 -0.77 1.98 -4.66 to 3.12 Baseline 200 <0.001 
      Time-point 9.49 0.002 
Communication 0.11 0.742 0.67 2.04 -3.34 to 4.69 Baseline 171 <0.001 
EQ-5D  1.82 0.178 -0.025 0.019 -0.062 to 0.012 Baseline 71 <0.001 
              
EQ-5D: VAS  0.76 0.385 -1.34 1.54 -4.38 to 1.69 Baseline 171 <0.001 
           Gender 5.22 0.023 
HbA1c          
mmol/mol 0.11 0.740 -0.40 1.22 -2.80 to 1.99 Baseline 330 <0.001 
 F(1,290) p Mean s.e. 95% CI  F(1,290) p 
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Table 3: Mixed models: mean effect at 3 & 6 months estimated from main model 
Outcome variable 
Time 
point 
Difference (Epic Pack– Treatment as usual) 
Mean s.e. 95% CI p 
Change 
(6mth-3mth) 
p 
Child self-report        
PedsQL: General         
Total score 3mth 0.52 1.26 (-1.96 to 2.99) 0.682 
-2.96 0.024 
 6mth -2.44 1.30 (-5.01 to 0.13) 0.063 
Physical functioning 3mth 2.16 1.59 (-0.96 to 5.29) 0.174 
-4.24 0.005 
 6mth -2.08 1.44 (-4.92 to 0.76) 0.151 
Emotional functioning 3mth -0.60 2.06 (-4.65 to 3.45) 0.769 
0.18 0.932 
 6mth -0.42 2.19 (-4.73 to 3.89) 0.848 
Social functioning 3mth 0.55 1.62 (-2.64 to 3.75) 0.734 
-1.21 0.455 
 6mth -0.66 1.72 (-4.03 to 2.72) 0.701 
School functioning 3mth -0.01 1.63 (-3.21 to 3.20) 0.997 
-5.78 0.002 
 6mth -5.79 1.74 (-9.21 to -2.36) 0.001 
PedsQL: Diabetes         
Total score 3mth 1.23 1.39 (-1.50 to 3.96) 0.375 
-3.11 0.020  6mth -1.88 1.46 (-4.76 to 1.00) 0.200 
Diabetes symptoms 3mth 0.14 1.72 (-3.26 to 3.53) 0.938 
-0.45 0.803 
 6mth -0.31 1.81 (-3.88 to 3.26) 0.865 
Treatment barriers 3mth 1.77 1.91 (-1.98 to 5.52) 0.355 
-4.07 0.042 
 6mth -2.30 2.05 (-6.34 to 1.74) 0.263 
Treatment adherence 3mth -0.08 1.69 (-3.40 to 3.25) 0.964 
-4.76 0.009  6mth -4.68 1.74 (-8.10 to -1.25) 0.008 
Worry 3mth 5.87 2.19 (1.57 to 10.18) 0.008 
-5.29 0.028 
 6mth 0.58 2.37 (-4.09 to 5.25) 0.808 
Communication 3mth 3.66 2.10 (-0.47 to 7.80) 0.082 
-5.94 0.008  6mth -2.28 2.34 (-6.89 to 2.32) 0.330 
EQ-5D  3mth 0.013 0.023 (-0.032 to 0.059) 0.568 
-0.025 0.304  6mth -0.011 0.019 (-0.050 to 0.027) 0.555 
        
EQ-5D: VAS  3mth 0.58 1.83 (-3.02 to 4.18) 0.751 
1.04 0.569  6mth 1.62 2.03 (-2.37 to 5.60) 0.426 
        
Parent proxy        
PedsQL: General         
Total score 3mth 0.04 0.976 (-2.43 to 2.51) 0.976 
1.79 0.114 
 6mth 1.83 0.191 (-0.92 to 4.58) 0.191 
Physical functioning 3mth 1.53 1.53 (-1.49 to 4.55) 0.319 
1.39 0.399 
 6mth 2.92 1.66 (-0.36 to 6.19) 0.081 
Emotional functioning 3mth -2.44 2.10 (-6.58 to 1.71) 0.248 
3.93 0.068 
 6mth 1.49 2.20 (-2.84 to 5.81) 0.499 
Social functioning 3mth 1.16 1.60 (-1.99 to 4.30) 0.470 
-0.88 0.586  6mth 0.28 1.71 (-3.09 to 3.65) 0.870 
School functioning 3mth -0.53 1.72 (-3.91 to 2.85) 0.757 3.00 0.114 
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 6mth 2.47 1.70 (-0.88 to 5.82) 0.148 
PedsQL: Diabetes         
Total score 3mth -2.29 1.20 (-4.64 to 0.07) 0.057 
3.49 0.781 
 6mth 1.20 1.38 (-3.78 to 1.65) 0.440 
Diabetes symptoms 3mth -2.93 1.40 (-5.68 to -0.19) 0.036 
2.77 0.074 
 6mth -0.16 1.61 (-3.33 to 3.01) 0.920 
Treatment barriers 3mth -2.71 1.85 (-6.36 to 0.94) 0.145 
3.01 0.145 
 6mth 0.30 1.98 (-3.59 to 4.19) 0.880 
Treatment adherence 3mth -3.86 1.72 (-7.25 to -0.47) 0.026 
0.77 0.702  6mth -3.09 1.73 (-6.50 to 0.32) 0.076 
Worry 3mth 1.15 2.44 (-3.64 to 5.94) 0.637 
3.84 0.161  6mth -2.69 2.38 (-7.37 to 1.98) 0.258 
Communication 3mth 1.04 2.43 (-3.74 to 5.83) 0.668 
1.98 0.768 
 6mth 3.02 2.36 (-4.34 to 4.94) 0.898 
EQ-5D  3mth -0.024 0.023 (-0.069 to 0.020) 0.280 
-0.001 0.963 
  6mth -0.026 0.022 (-0.070 to 0.019) 0.254 
EQ-5D: VAS  3mth -2.00 1.78 (-5.50 to 1.51) 0.263 
1.31 0.484 
  6mth -0.69 1.82 (-4.28 to 2.90) 0.706 
HbA1c         
mmol/mol 3mth -0.63 1.36 (-3.31 to 2.04) 0.641 
0.45 0.765 
 6mth -0.19 1.46 (-3.07 to 2.70) 0.899 
 
Sensitivity analyses 
Our sensitivity analysis confirmed that participants with incomplete outcomes (withdrawals 
or those lost to follow up) did not change the findings of this trial.  
Post-hoc analysis  
Given the shortage of treatment effects and the varying size of the three age subgroups, we 
undertook post-hoc analysis to see if there was any evidence of an effect within individual 
age groups bands. We found no evidence of differences in outcomes by age group.     
Cost consequences 
We based economic analysis on 233 (80%) of the 293 children in the effectiveness analysis. 
We excluded 60 (20%) children with incomplete data on costs and service use because we 
could not be sure that these were missing at random.  The mean total intervention unit cost 
of producing and administering intervention kits was £185 (Table 4A).  The mean total cost 
(NHS costs including intervention kit and administration costs) was £136 (bootstrapped 95% 
CI: -£52, £296) higher for the intervention group than for the comparator group, but this 
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difference was not statistically significant (Table 4B). We undertook bootstrapping with 
1000 replicates to estimate a 95% confidence interval around this mean difference in costs 
and consequences between groups. For consequences, there were no significant mean 
differences for any outcome. Sensitivity analysis postulating that consultants instead of 
PDSNs see children in clinic but for the same 13.2 minutes, increased the mean difference in 
total costs of service use between groups from £136 to £182 (bootstrapped 95% confidence 
interval: -£9 to £339), but this difference was still not statistically significant.  
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Table 4A. Costs of producing and distributing self-management intervention kits and distributing them to participants by PDSNs in 
clinics in 2011 UK pounds (£)  
Notes: 
a. Including ‘treatment cost’ of producing and printing age-specific diabetes diaries, but not ‘research cost’ of developing these diaries. 
b. Including ‘treatment cost’ of estimated time of Paediatric Diabetes Specialist Nurses (PDSNs) in teaching children about the kit, but 
not ‘research cost’ of research nurses distributing the kit. 
 
Age group 6-10 years 11-15 years 16-18 years Across all ages 
Administration route Injection Pump Injection Pump Injection Pump 
Cost of self-management kit a (£) 11.57 16.67 12.09 17.19 22.07 28.29  
Cost of extra PDSN appointments b (£) 166.66 166.66 166.66 166.66 166.66 166.66  
Total cost per participant (£) 178.23 183.33 178.75 183.85 188.73 194.95 184.64 
Number in Intervention Group  49 9 66 8 21 5 158 
Total cost of intervention (£) 8733 1650 11798 1471 3963 975 28590 
Average cost per participant (£)       180.95 
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Table 4B. Health service use costs and consequences by allocated group over 6 months  
 
Intervention 
kits 
(n=158) 
Mean (SD) 
Treatment as 
usual 
(n=75) 
Mean (SD) 
Intervention minus 
treatment as usual 
(bootstrapped 95% CIs) 
Costs    
Primary care (£) a 67 (111) 61 (90) 6 (-22, 32) 
Secondary care (£) a 454 (524) 504 (648) -50 (-226, 103) 
EPIC intervention cost (£) a, b 181 (4) 0 (0) 181 
Total cost / participant (£) 702 (558) 566 (664) 136 (-52, 296) 
Consequences 
Participant self-report: 
QALYs  0.446 (0.0741) 0.447 (0.0784) -0.001 (-0.0209, 0.0189) 
Parent-proxy: 
QALYs 0.415 (0.0785) 0.418 (0.0831) -0.003 (-0.0238, 0.0188) 
Notes: 
a Mean (SD) total cost per participant (£) 
b Cost of intervention includes: the ‘treatment costs’ of producing and distributing the kit to participants by Paediatric Diabetes Specialist Nurses in 
clinics; those of producing and distributing the intervention diabetes diary; but not the ‘research costs’ of developing kit or diary. 
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Process Evaluation 
We present key findings from the process evaluation 12 to illustrate the wider context within 
which children were initially excited but thereafter did not engage as intended with diabetes 
self-management generally or use the standardised kits specifically.   We offer an 
explanation as to how the context was created for this mechanism to occur. 
 Normalisation in children’s self-management and relationships with professionals 
After initial excitement, most children said that they did not use the EPIC kits as intended; a 
few rejected them completely and put them out of sight, for example in the loft.  Analysis of 
the words, messages and images in children’s self-management information found that they 
generally presented rules to manage diabetes supported by images of being ‘normal’ like 
other children if they followed those rules and did what professionals said. The process 
evaluation showed that these authoritarian normalisation messages did not always resonate 
with children, especially teenagers, as they did not feel normal because their life was 
frequently defined by diabetes, which they disliked.  The presence of the EPIC kits and the 
messages they contained caused increasing levels of worry and anxiety. So they tried to hide 
diabetes by not making ‘self-management’ visible to themselves or others.  Hence few 
children took a diabetes diary to school or wanted to test their blood sugar levels.   
 
Children’s inability to associate blood glucose tests with better management  
Baseline questionnaires from 308 children and their parents at entry to the trial show that 
they knew how many times a day they should record their blood glucose.  In reality most 
children, especially teenagers and irrespective of allocation, did not use or even see the 
need to record or observe trends in blood glucose levels to titrate their insulin dose. Of 
those interviewed in the intervention treatment group, around half of 6-10 year olds, less 
than half of 11-15 year olds, but only around 20% of 16-18 year olds said that they or their 
parents recorded blood glucose levels; fewer still appeared to use levels to titrate insulin 
doses.  Children more commonly neglected the age-appropriate self-management 
information provided.  Many children thought that they were recording this information for 
the benefit of diabetes professionals and made no link between blood glucose testing and 
gaining better diabetes control.   
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Children’s ignorance of risky behaviour and long-term complications of diabetes 
By not titrating insulin doses to blood glucose levels, many children took risks with their 
diabetes-related health; many teenagers appeared unconcerned about the potential 
consequences.  Some parents said they wanted to protect their children from receiving 
information on risks and complications, whereas others wanted to expose their children to 
the reality of life threatening complications like renal failure.  Discourse analysis showed 
that: children’s diabetes information resources for ages 6-10 years rarely mentioned risks or 
complications of poorly controlled diabetes; while those for ages 11-15 years were usually 
vague about serious risks and long-term complications of poorly controlled diabetes.  In 
contrast information distributed on entry to adult diabetes services was explicit about risks 
of long-term complications and the resulting need for self-management to minimise these.  
 
Promotion of intervention by diabetes professionals and parents  
Most diabetes teams did not actively engage with the intervention kits or encourage their use 
in routine consultations. Around a third of children approached declined to participate.  Often 
there were modifications to intended intervention delivery; for example the research nurse, 
not a member of the child’s diabetes team, gave the kit and diary to the child.  There was little 
individualisation or tailoring of intervention kits.  Around half the PDSNs regulated the 
information given to children and knowingly withheld or removed information on lifestyle 
issues and risks of complications before distribution to children.  From the kit for ages 11-15 
distributed to 103 participants, professionals reported removing several topics as 
inappropriate: sex and beyond (12 times), drinking alcohol (11 times), body piercing (8 times), 
and carbohydrate awareness (4 times).  After children had received the kits, many parents 
had removed anything they thought unsuitable, notably the ‘lifestyle’ resources, if not already 
removed by the PDSN.  
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Discussion 
Principal findings 
This pragmatic trial found no evidence of benefit from age-appropriate diabetes self-
management kits for children.  Of the five dimensions of the Diabetes PedsQL, Worry 
showed adjusted scores significantly favouring self-management kits at three months but 
Treatment Adherence significantly favoured controls at six months.  Furthermore children 
using self-management kits reported significantly worse changes between three and six 
months on four of the five Diabetes PedsQL dimensions and thus on the total score.  There 
was no evidence of change in HbA1c; only 18% of participants in each group achieved 
recommended levels at 6 months.  This was apparently because the kits alienated children 
and parents, and their use of kits and recording of blood glucose was poor. Moreover five 29-
33 other contemporaneous UK trials of educational interventions for childhood diabetes 
reported no benefit and little rapport between children, their parents, clinic staff, and the 
interventions. The other five interventions comprised structured diabetes education, family-
based diabetes education and support 30-33 and training in communication skills29.  None of 
these six UK trials (including EPIC) showed any difference in HbA1c between groups; or 
evidence of any other benefit. EPIC is the first trial to make clear a deleterious intervention 
effect over time.   As fewer than 20% of all 2018 children across the six trials achieved 
glycaemic control (pre 2015 HbA1c target of  ≤58 mmol/mol),   this meant  that over 80% of 
children were at risk of serious complications.  All six trials reported concerns about 
intervention fidelity.  Attendance at additional diabetes teaching sessions was highly 
variable, and those with the highest HbA1c were least likely to attend. A recent systematic 
review of ten trials of education and psychoeducation interventions (Including the five trials 
above but excluding EPIC as HbA1c had not been fully analysed at the time) showed a non-
significant reduction in HbA1c attributable to the intervention (pooled SMD = -0.06, 95% CI: 
-0.21 to 0.09).34 
 
Our parallel analysis of the words and images in diabetes resources provides new insights 
into the potential source of the surprisingly adverse effects of the kits.  These stem in part 
from children’s rejection of ‘unwelcome’ information which labelled them as different in 
having diabetes and authoritarian instructions like ‘take me with you wherever you go’.  
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More generally the discourse of ‘normalisation’ through optimal management and insulin as 
a social enabler appears counterproductive in promoting desired behaviour change.  Poor 
relationships between children, parents and diabetes professionals is another reason for 
lack of ‘compliance’ with diabetes professionals’ expectations.  In short diabetes 
communicators do not yet know how to convey effective messages to children.  One trial 
(DEPICTED)29, which attempted to train health-care professionals do this, also failed to show 
any benefit.   
 
Strengths and weaknesses of this study 
We based the EPIC kit on extensive research with children, parents and professionals; and 
met international standards for patient information.12-13 We powered the EPIC trial to 
detect plausible effect sizes for the entire age-range, and surpassed recruitment targets.20,21 
Particular strengths included the preparatory discourse analysis of children’s diabetes self-
management information and the process evaluation in which children assessed the ways in 
which they received key diabetes self-management information. In retrospect the major 
weakness was the unpopularity of the EPIC kit. 
 
Interpretation  
Lack of progress in meeting the NICE target for HbA1c in children stimulated the 
commissioning of this and five other contemporaneous trials by UK funders to test various 
approaches to promote optimal self-management.  Other promising developments since the 
delivery of this trial, include electronic management systems, diabetes phone and iPad 
applications, and personalised web-based diabetes training programmes.27-30 However 
these are unlikely to benefit children if, despite receiving good information, they still do not 
make the link between blood glucose testing and achieving glycaemic control through 
insulin, diet and lifestyle management.   
In contrast, international studies show that children can achieve acceptable glycaemic 
control through investment in structured education and patient management following 
diagnosis, with outcomes ranging from 29% to over 50% of children achieving an HbA1c 
level less than ≤58mmol/mol 35-36 this is much higher than the 18% achieved by EPIC & the 
UK in general.  The Hvidøre Study Group 35 identified management from the diagnosis of the 
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disease, positive and shared attitudes within diabetes teams and greater patient 
empowerment as factors that enhanced glycaemic control.  Though we understand these 
factors, we do not know why UK children cannot achieve similar standards.  
Implications for practice and research  
Our process evaluation and discourse analysis identified two problems which have not yet 
been adequately addressed.  First, we need to understand better how children respond to 
‘authority’ in relationships with diabetes professionals.  Expected regular attendance at 
outpatient clinics, the normative nature of most self-management information, and the 
withholding of requested lifestyle information all reinforce the power imbalance.  Despite 
the intended focus on ‘normalisation’, children feel different, dislike being different, and 
tend to reject any intervention that reminds them of that difference.  The second problem is 
that children, parents and professionals cannot reconcile clinical risk definitions and 
personal ones.  Children assess risks differently from diabetes professionals and take 
rational decisions about what is acceptable for them.  To overcome this, professionals may 
need to address risk collaboratively rather than hierarchically and this would require a 
complete rethink as to how diabetes services are designed and delivered.     Motivational 
interviewing has, for example, been shown to be an effective method of facilitating 
behavioural changes in teenagers with type 1 diabetes with subsequent improvement in 
their glycaemic control.37  
There are also implications for trial methods and conduct.  First, we need to encourage 
research and clinical teams to implement complex interventions like this rigorously but also 
flexibly.  Secondly, as the care of children’s diabetes varies widely across the UK, there is 
merit in engaging the diabetes teams likely to contribute to a planned trial in design and 
planning.   
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Figures 
Figure 1.  CONSORT diagram from screening to analysis. 
 
Figure 2. CONSORT diagram, showing missing data from screening to analysis 
